Mar 5, 2019
iCo Therapeutics Inc. Announces the Issuance of 3,600,000 Units Pursuant to its Non-Brokered Private Placement
Feb 25, 2019
iCo Therapeutics Inc. Announces the Issuance of 14,400,000 Units Pursuant to its C$1,250,000 Non-Brokered Private Placement

View All News (+)

Enter Your Email to Sign Up for
iCo Therapeutics Updates

About iCo Therapeutics

iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus areas and if so the Company will seek to capture further value via partnerships. iCo shares trade on the TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.

Copyright 2015 ICO Therapeutics | Disclaimer